OraSure Technologies, Inc. (OSUR)
Price:
3.08 USD
( + 0.28 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
QuidelOrtho Corporation
VALUE SCORE:
5
2nd position
DENTSPLY SIRONA Inc.
VALUE SCORE:
9
The best
Pro-Dex, Inc.
VALUE SCORE:
10
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
NEWS
OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-25 20:17:47OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
Agape ATP (NASDAQ:ATPC) vs. OraSure Technologies (NASDAQ:OSUR) Head to Head Survey
defenseworld.net
2026-02-20 03:03:01OraSure Technologies (NASDAQ: OSUR - Get Free Report) and Agape ATP (NASDAQ: ATPC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Analyst Recommendations This is a breakdown of
OraSure to Launch OraQuick™ HIV Self-Test in Canada
globenewswire.com
2026-02-10 08:05:00BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada.
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
globenewswire.com
2026-02-09 16:15:00BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
globenewswire.com
2026-01-15 13:00:00BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
businesswire.com
2026-01-15 08:30:00LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the “Board”) at the 2026 Annua.
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
zacks.com
2026-01-06 12:41:46OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates
globenewswire.com
2025-12-17 13:23:00BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund's founder, Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
businesswire.com
2025-12-17 08:00:00LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai's intention to nominate two highly-qualified candidates, John Bertrand, CEO of Digital Diagnostics, and Rishi Bajaj, President and CI.
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-05 20:11:10OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.
OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
2025-11-05 19:51:10OraSure Technologies (OSUR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.01 per share a year ago.
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
globenewswire.com
2025-10-29 07:30:00BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025.
OraSure Technologies Appoints Steven K. Boyd to its Board of Directors
globenewswire.com
2025-10-28 16:22:00Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K.
Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say
reuters.com
2025-09-09 06:19:33Altai Capital Management is preparing to launch a board fight at OraSure Technologies after the hedge fund, already one of the biggest owners of the medical device maker, increased its holdings, two people familiar with the matter told Reuters.
Exclusive: Healthcare entrepreneur's letter threatens 'adversarial path' after OraSure Tech rebuffs bid
reuters.com
2025-08-25 12:12:50Prominent healthcare entrepreneur Ron Zwanziger warned on Monday he may pursue a more "adversarial path" if the OraSure Technologies board continues to resist his offer to buy the medical devices company, according to a letter seen by Reuters.
OraSure (OSUR) Q2 Revenue Falls 43%
fool.com
2025-08-05 21:41:04OraSure (OSUR) Q2 Revenue Falls 43%
OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-25 20:17:47OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
Agape ATP (NASDAQ:ATPC) vs. OraSure Technologies (NASDAQ:OSUR) Head to Head Survey
defenseworld.net
2026-02-20 03:03:01OraSure Technologies (NASDAQ: OSUR - Get Free Report) and Agape ATP (NASDAQ: ATPC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability. Analyst Recommendations This is a breakdown of
OraSure to Launch OraQuick™ HIV Self-Test in Canada
globenewswire.com
2026-02-10 08:05:00BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada.
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
globenewswire.com
2026-02-09 16:15:00BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026.
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
globenewswire.com
2026-01-15 13:00:00BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
businesswire.com
2026-01-15 08:30:00LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has nominated two highly-qualified candidates, John Bertrand, Co-Founder of Digital Diagnostics, and Rishi Bajaj, President and CIO of Altai, for election to the OraSure Board of Directors (the “Board”) at the 2026 Annua.
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
zacks.com
2026-01-06 12:41:46OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
OraSure Technologies Issues Statement Regarding Altai Capital's Intent to Nominate Director Candidates
globenewswire.com
2025-12-17 13:23:00BETHLEHEM, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital (“Altai”) has notified the Company of its intent to nominate two candidates, including the fund's founder, Rishi Bajaj, to stand for election to the Company's Board of Directors (the “Board”) at its 2026 Annual Meeting of Stockholders.
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
businesswire.com
2025-12-17 08:00:00LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. (“Altai”), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter notifying the OraSure Board of Directors (the “Board”) of Altai's intention to nominate two highly-qualified candidates, John Bertrand, CEO of Digital Diagnostics, and Rishi Bajaj, President and CI.
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
seekingalpha.com
2025-11-05 20:11:10OraSure Technologies, Inc. ( OSUR ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Jason Plagman - Vice President of Investor Relations Carrie Eglinton Manner - President, CEO & Director Kenneth McGrath - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the OraSure Technologies, Inc. 2025 Third Quarter Earnings Conference Call.
OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
2025-11-05 19:51:10OraSure Technologies (OSUR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.01 per share a year ago.
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
globenewswire.com
2025-10-29 07:30:00BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025.
OraSure Technologies Appoints Steven K. Boyd to its Board of Directors
globenewswire.com
2025-10-28 16:22:00Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K.
Exclusive: Altai Capital lays groundwork for board fight at OraSure Technologies, sources say
reuters.com
2025-09-09 06:19:33Altai Capital Management is preparing to launch a board fight at OraSure Technologies after the hedge fund, already one of the biggest owners of the medical device maker, increased its holdings, two people familiar with the matter told Reuters.
Exclusive: Healthcare entrepreneur's letter threatens 'adversarial path' after OraSure Tech rebuffs bid
reuters.com
2025-08-25 12:12:50Prominent healthcare entrepreneur Ron Zwanziger warned on Monday he may pursue a more "adversarial path" if the OraSure Technologies board continues to resist his offer to buy the medical devices company, according to a letter seen by Reuters.
OraSure (OSUR) Q2 Revenue Falls 43%
fool.com
2025-08-05 21:41:04OraSure (OSUR) Q2 Revenue Falls 43%